The Joint Meeting of ASCI, AAP, and APS 2027

Dr. Javid trained in medicine at the University of Cambridge, completed residency in general (internal) medicine in London and returned to Cambridge as a Medical Research Council (MRC) Clinical Training Fellow for graduate studies under Paul Lehner, investigating cross-presentation by human dendritic cells to cytotoxic T lymphocytes. Following specialist training in infectious diseases, he went to Harvard as an MRC Clinician Scientist Fellow to train with Eric Rubin in mycobacterial genetics, where he first became interested in ‘unique’ aspects of the mycobacterial translation apparatus. From 2011 to 2020 he was Principal Investigator at the Tsinghua University School of Medicine, Beijing, China. Dr. Javid’s group focuses on tuberculosis pathophysiology from the perspective of both the pathogen and host immunity, and are interested in the role of translational errors in adaptation by Mycobacterium tuberculosis and the role and function of humoral immunity to tuberculosis. Dr. Javid served as Co-Chair of the B cell / Antibody group of the Collaboration for TB Vaccine Discovery from 2018-2023 and serves on the WHO working group for a tuberculosis vaccine roadmap. He is currently an Investigator of the Wellcome Trust and was elected to the ASCI in 2023.

Leonard I. Zon, MD is the Grousbeck Professor of Pediatric Medicine at Harvard Medical School, Investigator at Howard Hughes Medical Institute, and Director of the Stem Cell Program, Boston Children’s Hospital. He is founder and former president of the International Society for Stem Cell Research and chair of the Executive Committee of the recently formed Harvard Stem Cell Institute. Dr. Zon is internationally recognized for his pioneering work in the fields of stem cell biology and cancer genetics. He has been the pre-eminent figure in establishing the zebrafish as an invaluable genetic model for the study of the blood and hematopoietic development. His laboratory focuses on the developmental biology of hematopoiesis and cancer; have undertaken chemical genetic approaches to blood development finding that prostaglandins upregulates blood stem cells; and have developed suppressor screening genetics and zebrafish models of cancer. Dr. Zon served as 2004-2005 ASCI President, is an elected member of the NAM (2005), AAAS (2008), and NAS (2022), and was awarded the E. Donnall Thomas Lecture and Prize from American Society of Hematology, the ISEH Donald Metcalf Lecture Award and the AACR-Irving Weinstein Foundation Distinguished Lecture Award.

2022-2023 ASCI President-Elect, Chief of the Division of Nephrology and the Joseph Friedman Professor at Washington University in St. Louis, and member of the Board of Scientific Counselors for the National Institute of Diabetes and Digestive and Kidney Diseases.

Elaine Fuchs is renowned for her research in skin biology, its stem cells and associated genetic disorders, particularly cancers. She is an Investigator of the Howard Hughes Medical Institute and Rebecca C. Lancefield Professor of Mammalian Cell Biology and Development at The Rockefeller University. Dr. Fuchs’ awards and honors include the US National Medal of Science, L’Oreal-UNESCO Award, Albany Prize in Medicine, March of Dimes Prize, International Pezcoller Award in Cancer Research, EB Wilson Award in Cell Biology, Vanderbilt Prize, AACR Clowes Award, ISSCR McEwen Award for Innovation in Stem Cell Research, and the Canada Gairdner International Award. She is an honorary member of the National Academy of Sciences, National Academy of Medicine, American Philosophical Society, Pontifical Academy of Sciences, and the Royal Society.

Dr. Paczesny is Professor and Chair of the Department of Microbiology and Immunology as well as Co-Leader of the Cancer Immunology Program at the Hollings Cancer Center, Medical University of South Carolina. Dr. Paczesny serves on the ASCI Council, is Chair of the ASCI Diversity, Inclusion, and Equity Committee, and Co-Chair of the Center for International Blood and Marrow Transplant Immunobiology working group.

Dr. MacKenzie is a pediatric and fetal surgeon focused on developing better ways to diagnose and treat genetic diseases before birth. She runs a translational research lab examining fetal immunology and maternal-fetal tolerance. She recently co-founded the Center for Maternal-Fetal Precision Medicine. Dr. MacKenzie has moved two fetal molecular therapies from the lab to phase 1 clinical trials: in utero hematopoietic stem cell transplantation to treat fetuses with alpha thalassemia and in utero enzyme replacement therapy in fetuses with lysosomal storage disorders. Her honors include the American College of Surgeons’ Jacobson Award and election to the National Academy of Medicine in 2022. She was elected to the American Society for Clinical Investigation in 2021.

Elected to ASCI membership in 2022, Dr. Arboleda serves on the ASCI Physician-Scientist Development Committee.

Dr. Glass’s laboratory has had a long-standing interest in elucidating the molecular mechanisms by which sequence specific transcription factors, co-activators, and co-repressors regulate the development and function of macrophages. Current studies use a combination of genetics and genomics to define general molecular mechanisms that establish macrophage identity and cell-specific responses to homeostatic and pathogenic signals in mouse models and human subjects, with the goal to understand and modify pathological programs of macrophage gene expression that promote the development of atherosclerosis, diabetes, hepatitis, and neurodegenerative diseases. Dr. Glass’s many honors include the Endocrine Society’s Ernst Oppenheimer Award, and election to the Academy of Arts and Sciences (2014), the National Academy of Medicine (2015), and the National Academy of Sciences (2017). Dr. Glass was elected to the ASCI in 1995.

Dr. Saba is a recent recipient of the Nucleate Pillar Venture Prize. She is currently a member of the ASCI’s Diversity, Equity, and Inclusion Committee.

Bruce Beutler, MD, is a Regental Professor at the UT Southwestern Medical Center, where he directs the Center for the Genetics of Host Defense. Dr. Beutler studied medicine at the University of Chicago. Early in his career he isolated mouse TNF and discovered its inflammatory properties, later developing TNF inhibitor proteins that found widespread use in clinical medicine. He then identified Toll-like receptor 4 as the mammalian sensor of bacterial lipopolysaccharides. These groundbreaking studies earned Dr. Beutler the 2011 Nobel Prize in Physiology or Medicine (with J. Hoffmann and R. Steinman). In the past decade, using statistical computation and artificial intelligence to discover point mutations that cause any measurable phenotype in real time, Dr. Beutler and his team have identified thousands of mutations in hundreds of genes that disrupt normal immune function, development, metabolism, neurobehavioral function, and other biological processes of interest. Dr. Beutler is a member of the ASCI (elected in 1990, profile here), the National Academy of Medicine (2008), the National Academy of Sciences (2008), and the American Academy of Arts & Sciences (2013). He is recipient of the Balzan Prize (2007), Albany Medical Center Prize in Medicine and Biomedical Research (2009), the Shaw Prize (2011), and the ASCI Stanley J. Korsmeyer Award (2013).